Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7093)
All Articles published online
|
Publishing Process of This Article
|
Mar 27, 2024 (publication date) through Dec 31, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Sato-Espinoza K, Chotiprasidhi P, Huaman MR, Díaz-Ferrer J. Update in lean metabolic dysfunction-associated steatotic liver disease. World J Hepatol 2024; 16(3): 452-464 [PMID: 38577539 DOI: 10.4254/wjh.v16.i3.452] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Sato-Espinoza K, Chotiprasidhi P, Huaman MR, Díaz-Ferrer J. Update in lean metabolic dysfunction-associated steatotic liver disease. World J Hepatol 2024; 16(3): 452-464 [PMID: 38577539 DOI: 10.4254/wjh.v16.i3.452] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i3/452.htm |
| Number | Citing Articles |
| 1 |
E. E. Zabotina, Yu. A. Khabarova, N. Yu. Stukova. Metabolic dysfunction associated steatotic liver disease in lean patients. Diagnostic and treatment challenges. Experimental and Clinical Gastroenterology 2025; (9): 96 doi: 10.31146/1682-8658-ecg-229-9-96-109
|
| 2 |
Stavros P. Papadakos, Chara Georgiadou, Eva Kassi, Rallia-Iliana Velliou, Antonios Chatzigeorgiou. Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery. Expert Opinion on Drug Discovery 2025; : 1 doi: 10.1080/17460441.2025.2579124
|
| 3 |
Priyankar Dey. The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what’s different?. Frontiers in Endocrinology 2025; 16 doi: 10.3389/fendo.2025.1693123
|
| 4 |
Jan Best, Julia Kälsch, Marcin Krawczyk, Paul Manka, Ali Canbay, Hartmut Schmidt, Leonie Jochheim. Metabolische Dysfunktion-assoziierte steatotische Lebererkrankung und hepatozelluläres Karzinom. Die Gastroenterologie 2025; 20(2): 123 doi: 10.1007/s11377-025-00878-z
|
| 5 |
Indrajit Bhattacharya, Deep Kumar Maity, Amit Kumar, Sampriti Sarkar, Teeshyo Bhattacharya, Amrita Sahu, Remya Sreedhar, Somasundaram Arumugam. Beyond obesity: lean metabolic dysfunction-associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancement. Naunyn-Schmiedeberg's Archives of Pharmacology 2025; 398(10): 13647 doi: 10.1007/s00210-025-04257-x
|
| 6 |
Gerard Stupecki, Emilia Kowalczyk, Agnieszka Ciba-Stemplewska, Magdalena Dolecka-Ślusarczyk, Iwona Gorczyca-Głowacka. Metabolic dysfunction-associated steatotic liver disease: Prevalence and progression in lean patients. Polish Annals of Medicine 2025; : 1 doi: 10.29089/paom/203734
|
| 7 |
Lampros Chrysavgis, Evangelos Cholongitas. From NAFLD to MASLD: what does it mean?. Expert Review of Gastroenterology & Hepatology 2024; 18(6): 217 doi: 10.1080/17474124.2024.2374472
|
| 8 |
Fabio Novielli, Carlo De Matteis, Antonio Moschetta, Lucilla Crudele. Non-invasive assessment of liver fibrosis in MASLD: the need of sex-adjusted scores. Expert Review of Gastroenterology & Hepatology 2025; 19(10): 1081 doi: 10.1080/17474124.2025.2557243
|
| 9 |
Su-Qun Li, Jin-Hua Wu, Ying Zhou, Chen-Xi Wang, Li Xie, Si-Ying Liu, Yu-Zhi Su, Wei He, Huan Chen, Wei-Wei Zhong, Yi-Huai He. Hepatocyte nuclear factors dynamically regulate triglyceride metabolic reprogramming in metabolic dysfunction-associated steatotic liver disease: Mechanisms and implications. World Journal of Hepatology 2025; 17(10): 109898 doi: 10.4254/wjh.v17.i10.109898
|
| 10 |
Fabien Wauquier, Vivien Chavanelle, Annie Bouchard-Mercier, Line Boutin-Wittrant, Yolanda F. Otero, Stéphanie Krisa, Josep Valls, Florian Le Joubioux, Bruno Pereira, Véronique Roux, Nicolas Macian, Gisèle Pickering, Véronique Sapone, Murielle Cazaubiel, Auriane Bron, Sébastien Peltier, Stéphanie Blanquet, Pascal Sirvent, Yohann Wittrant. Bioavailable human metabolites from TOTUM-448 (plant-based formulation) maintain liver cell functionality in a hyperlipidic context that drives MASLD onset. Scientific Reports 2025; doi: 10.1038/s41598-025-32556-z
|
| 11 |
Karina Sato-Espinoza, Perapa Chotiprasidhi, Estefanía Liza, Zuly Placido-Damian, Javier Diaz-Ferrer. Evolution of liver transplantation in the metabolic dysfunction-associated steatotic liver disease era: Tracking impact through time. World Journal of Transplantation 2024; 14(4): 98718 doi: 10.5500/wjt.v14.i4.98718
|